Colorcon invests in new film coating manufacturing plant in Brazil
Production of commercial-scale product scheduled for January 2017.
Colorcon has announced its investment in a new film coating manufacturing plant in Indaiatuba, São Paulo State, Brazil, supporting the continued growth of the pharmaceutical industry in South America. The construction is scheduled for completion by October 2016 with the production of commercial-scale product scheduled for January 2017. Strategically located, the site will produce GMP film coating products for the pharmaceutical and nutritional markets in South America, including Argentina, Brazil, Chile, Paraguay and Uruguay
Martti Hedman, CEO, Colorcon Inc. explains the significance of Colorcon’s investment as another example of our strategy to position manufacturing facilities close to our customers. “We want to make it easy for customers to work with Colorcon. This facility allows our customers to take advantage of shorter lead times on all of our film coating products, and reduces the risk of importation delays. In addition, the Indaiatuba facility is another important step in further securing the supply chain for our customers, by providing a South American component in Colorcon’ s Business Continuity Plan, with the capability to supply and export film coatings with the same quality, consistency and equivalency for product manufactured in our other six production plants around the world.”
Perry Cozzone, President – Americas added: “Colorcon is committed to providing the highest quality products and superior service to meet our customer's needs around the world. This investment reinforces our dedication to providing exceptional support we believe our customers deserve while providing greater flexibility in the scheduling of their production, ultimately leading to their products reaching the market faster.”
Colorcon Brazil will continue to support customers across the region with formulation and development of pharmaceutical products through the Technical Service Laboratory already established at Cotia, Sao Paulo. Originally opened in 2000, this support facility has continued to provide samples and applications support for over 16 years in the region.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.